The expression and molecular mechanisms of SH2B in hepatocarcinoma

doi:10.3760/cma.j.issn.1673422X.2015.08.006

Abstract

Abstract: ObjectiveTo observe the expression and influence of SH2B in hepatocarcinoma, and to investigate the molecular mechanisms of canceration in hepatocarcinoma. MethodsBy using SABC imunohistochemistry, the expressions of SH2B were detected in 27 cases of hepatitis, 29 cases of hepatocirrhosis and 47 cases of hepatocarcinoma. Hepatocarcinoma cell (HepG) 2 with a lowexpressed SH2B was selected using immunofluorescence assay. There were 3 groups: the transfected group (transfected with pcDNA3.1SH2B), the vector group (transfected with pcDNA3.1) and the blank group (without transfection). After gene transfection, SH2B expression was detected by Western blotting; cell proliferation was measured by MTT assay; cell colony was counted by colony formation test; and cell cycle was analyzed by flowcy tometer. ResultsThe positive rate of SH2B in hepatocarcinoma (95.7%) was significantly higher than 55.2% in hepatocirrhosis (χ2=18.64, P＜0.01) and 25.9% in hepatitis (χ2=40.01, P＜0.01). After being transfected with pcDNA 3.1SH2B, SH2B expression dramatically increased in HepG2 cells. After cultured for 48 h, the average optical density value of the transfected group was 1.12±0.19, obviously higher than 0.45±0.11 in the vector group (t=-31.55, P＜0.01), which indicated that cells proliferation was significantly enhanced after being transfected with SH2B. The cell colony numbers of the transfected group was 166±14, significantly higher than 82±8 in the vector group (t=-20.33, P＜0.01) and 78±9 in the blank group (t=-19.64, P＜0.01), which indicated that the cell colony numbers increased after being transfected with SH2B. The S stage cells of the transfected group was (45.7±5.8)%, significantly higher than (19.4±4.7)% in the vector group (t=-20.33, P＜0.01) and (20.5±5.1)% in the blank group (t=-34.69, P＜0.01), which indicated that SH2B could enhance promote cell cycle of HepG2 cells. ConclusionThe expression of SH2B in hepatocarcinoma is high, and it may be involved in the canceration of hepatocarcinoma though promoting cell cycle, cell proliferation and cell transformation.

Key words: Liver neoplasms, SH2B, Molecular mechanisms

HUA Jian-Jiang, TANG Fa-Qing, DUAN Chao-Jun, YUAN Yong-Mei, HE Ya, CHEN Wang, WANG Qi-Yun. The expression and molecular mechanisms of SH2B in hepatocarcinoma[J]. Journal of International Oncology, 2015, 42(8): 580-584.

References

［1］ Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002［J］. CA Cancer J Clin, 2005, 55(2): 74108. ［2］李建国, 华建江, 黄大毛, 等. SH2B在结肠癌组织中的表达及临床意义［J］. 中国现代医学杂志, 2010, 20(13): 20042007. ［3］张春芳, 陈伟, 黄琼辉, 等. SH2B在非小细胞肺癌中的表达［J］. 中华实验外科杂志, 2009, 26(10): 13601362. ［4］张航, 段朝军, 张恒, 等. 接头蛋白SH2B1在食管癌中的表达及意义［J］. 中南大学学报：医学版, 2013, 38(2): 125131. ［5］黄大毛, 李建国, 陈宇, 等. SH2B对结肠癌HT29细胞增殖的影响［J］. 中国普通外科杂志, 2010, 19(7): 768773. ［6］张磊, 李玉民. 肝癌的分子靶向治疗进展［J］. 国际外科学杂志, 2011, 38(10): 700703. ［7］ Guarino M. Src signaling in cancer invasion［J］. J Cell Physiol, 2010, 223(1): 1426. ［8］ Songyang Z, Cantley LC. ZIP codes for delivering SH2domains［J］. Cell, 2004, 116(2 Suppl): S4143. ［9］ Chen L, CarterSu C. Adapter protein SH2B beta undergoes nucleocytop lasmic shuttling: imp lications for nerve growth factor induction of neuronal differentiation［J］. Mol Cell Biol, 2004, 24(9): 36333647. ［10］ Duan C, Li M, Rui L. SH2B promotes insulin receptor substrate 1(IRS1)and IRS2mediated activation of the phosphatidylinositol 3kinase pathway inresponse to leptin［J］. J Biol Chem, 2004, 279(42): 4368443691. ［11］段朝军, 李萃, 汤参娥, 等. SH2Bβ调控JAK2/STAT3在肥胖症发病中的分子机制［J］. 中华内分泌代谢杂志, 2009, 25(1): 9091. ［12］张斌, 钟德玝, 王群伟, 等. JAK/STAT信号通路与肝细胞性肝癌的肿瘤进展和预后的相关性研究［J］. 细胞与分子免疫学杂志, 2010, 26(4): 368373. ［13］唐发清, 李建国, 陈宇, 等. SH2B与结肠癌细胞运动和迁移相关性的研究［J］. 中华肿瘤防治杂志, 2011, 18(1): 14.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells [J]. Journal of International Oncology, 2023, 50(4): 241-243.
[6]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke. Diagnostic value of serum TIM-3 in patients with liver cancer [J]. Journal of International Oncology, 2022, 49(9): 537-542.
[7]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[8]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng. Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer [J]. Journal of International Oncology, 2022, 49(10): 592-596.
[9]	Yang Chi, Luo Changjiang. Research progress on the background of inflammation， immunity and cholesterol metabolism in colorectal cancer [J]. Journal of International Oncology, 2022, 49(10): 630-634.
[10]	Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer [J]. Journal of International Oncology, 2022, 49(10): 635-638.
[11]	Du Jiahang, Chen Dong, Chen Yaoting. Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2021, 48(9): 572-.
[12]	Han Baojun. Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance [J]. Journal of International Oncology, 2021, 48(7): 415-419.
[13]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[14]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang. Progress of biomarkers in liver cancer [J]. Journal of International Oncology, 2021, 48(4): 241-245.
[15]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing. IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway [J]. Journal of International Oncology, 2021, 48(12): 711-715.